Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 7/20 | 0.45 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | PDE2A | O00408 | 3/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.34 |
| ▸ | FPR1 | P21462 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18282858 | 0.85 | PDE2A (0.49) | PDE2A | |
| SCHEMBL20150745 | 0.84 | PDE2A (0.46) | RETNTRK1PIM1PDE2AALOX5 | |
| SCHEMBL20202567 | 0.83 | PDE2A (0.47) | RETPDE2AALOX5MAPTRIPK2 | |
| SCHEMBL18291879 | 0.82 | PDE2A (0.52) | PDE2AALDH1A1 | |
| SCHEMBL31194537 | 0.78 | RET (0.50) | RET | |
| SCHEMBL20150735 | 0.78 | LMNA (0.46) | RETMAPTALDH1A1HPGDLMNA | |
| SCHEMBL18290658 | 0.76 | PDE2A (0.50) | RETPDE2AALOX5MAPTALDH1A1 | |
| SCHEMBL18283117 | 0.76 | PDE2A (0.69) | RETPDE2AALOX5MAPTALDH1A1 | |
| SCHEMBL18283324 | 0.74 | KDM4E (0.44) | RETNTRK1PIM1MAPTALDH1A1 | |
| SCHEMBL18290696 | 0.72 | PDE2A (0.49) | PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180148453-A1 | DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148453-A1 | DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | PDE12, PDE2A, PDE4D | RET 1879/4885NTRK1 3244/4885PIM1 2376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.